Determining the Impact of Packaging and Logistics on the CAR-T Clinical Pipeline

Sept. 14 presentation addresses the systematic study of the impact of logistics decisions on the integrity of critical biomarkers and active clinical product and data generation.

Sept. 14 presentation addresses the systematic study of the impact of logistics decisions on the integrity of critical biomarkers and active clinical product and data generation.
Sept. 14 presentation addresses the systematic study of the impact of logistics decisions on the integrity of critical biomarkers and active clinical product and data generation.

Logistics firm Cryoport, Inc. announced that Dr. Mark Sawicki, Chief Commercial Officer, is scheduled to present at the 2nd Annual CAR &TCR Summit 2016 in Boston.

He will present, “Critical Assessment of the Impact of Packaging and Logistics Decisions on the CAR-T Clinical Pipeline,” Wednesday, Sept. 14 at 5:10 p.m. at Booth 11, along with Jim Reiner, Senior Product Manager, UPS.

At this time, little peer-reviewed research exists on the impact of logistics strategies including fulfillment, packaging, and transport on clinical sample, product, and data integrity, in particular in the management of regenerative therapies. In response, in conjunction with company partners and clients, Cryoport conducted a systematic study of the impact of logistics decisions on the integrity of critical biomarker and active clinical product and the subsequent data generation. This data will be discussed in relation to its impact on clinical progression in the CAR-T space, including:

• Determining the appropriate logistics strategy to ensure data integrity

• Supporting companies’ efforts to handle important cold chain shipping needs from clinical trials to commercial launch

• Meeting the distribution, transportation and regulatory requirements for product development and commercialization

"We are excited about the results of this study and are very enthusiastic about the utilization of this data in relation to its impact on logistics decisions when evaluating clinical progression in the CAR-T space,” says Sawicki. “We appreciate the contributions of our partners and clients who participated in this study, and look forward to utilizing the study results to more effectively determine optimal transport conditions in supporting our clients efforts to handle important biomarkers and CAR-T active clinical product from clinical trials to commercial launch."

Companies in this article
More in Logistics/supply chain